文献速递垂体与肾上腺疾病性腺与生殖内分泌

硫酸镁可能揭示亚临床血管加压素酶过多性AVP紊乱

Magnesium sulfate may unmask subclinical excess vasopressinase-induced arginine vasopressin disorder.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文报告一例双胎妊娠妇女在持续静脉输注硫酸镁治疗先兆早产后突发口渴、多饮和多尿,初疑为AVP缺乏,但去氨加压素可控制症状且分娩后无需继续使用,不符合AVP缺乏典型病程。胎盘重量近典型单胎两倍,分娩前血清血管加压素酶显著升高,高渗盐水试验提示血管加压素酶过多降解AVP导致血浆AVP水平被低估。自2021年起共遇到8例类似病例,提示硫酸镁相关妊娠期AVP紊乱可能合并亚临床血管加压素酶过多性AVP紊乱。

要点

  • 硫酸镁治疗先兆早产期间出现口渴、多饮、多尿需警惕妊娠期AVP紊乱。
  • 血管加压素酶过多可降解AVP,导致血浆AVP水平假性降低,易误诊为AVP缺乏。
  • 分娩后症状迅速缓解、去氨加压素可停用,不符合典型AVP缺乏病程。

核心结论

  • 硫酸镁相关妊娠期AVP紊乱可能由亚临床血管加压素酶过多性AVP紊乱被揭示所致。
  • 过去4年遇到9例此前未报告的硫酸镁相关妊娠期AVP紊乱,提示临床可能漏诊。

研究设计与样本

  • 病例报告:一例26岁双胎妊娠妇女因先兆早产接受持续静脉硫酸镁治疗。
  • 结合自2021年以来遇到的8例类似病例进行总结。

主要发现

  • 硫酸镁输注次日突发口渴、多饮、多尿,血浆AVP极低且尿呈低渗,初疑AVP缺乏。
  • 去氨加压素有效控制症状,但分娩后次日即无需使用,不符合AVP缺乏典型病程。
  • 娩出胎盘重量近典型单胎两倍,分娩前血清血管加压素酶显著升高。
  • 分娩后不久高渗盐水输注试验提示血管加压素酶过多降解AVP致血浆AVP水平被低估。

临床怎么用

  • 妊娠期使用硫酸镁期间出现多饮多尿,应鉴别血管加压素酶过多性AVP紊乱。
  • 分娩后症状迅速缓解且去氨加压素可停用者,不支持典型AVP缺乏。
  • 怀疑血管加压素酶过多时,可结合胎盘重量及血清血管加压素酶水平评估。

局限性

  • 仅为病例报告及小样本观察,不能确立因果关系。
  • 机制推测基于个别病例,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Gestational arginine vasopressin (AVP) disorder is classified into 3 categories: AVP deficiency (AVP-D), AVP resistance, and excess vasopressinase-induced AVP disorder. This is the first case report of gestational AVP disorder linked with magnesium sulfate administration. CASE DESCRIPTION: A 26-year-old woman pregnant with twins was admitted to our hospital with threatened preterm labor (TPL). The day after continuous intravenous magnesium sulfate administration for TPL was initiated, the patient suddenly developed thirst, polydipsia, and polyuria. Because the plasma AVP level was extremely low and the urine was hypotonic, AVP-D was initially suspected. Her symptoms were effectively controlled using desmopressin. However, its administration became unnecessary the day after delivery, inconsistent with the typical clinical course of AVP-D. The removed placenta was nearly twice as heavy as that in typical singleton cases, and serum vasopressinase levels immediately before delivery were markedly elevated. The results of the hypertonic saline infusion test performed soon after delivery suggested an underestimation of plasma AVP levels due to AVP degradation by excess vasopressinase. We have encountered 8 similar cases since 2021, suggesting that coexisting subclinical excess vasopressinase-induced AVP disorder may contribute to the development of magnesium sulfate-associated gestational AVP disorder. The inhibition of AVP secretion from the posterior pituitary gland by markedly increasing circulating magnesium ions may be associated with the manifestation of subclinical excess vasopressinase-induced AVP disorder. CONCLUSION: We encountered 9 cases of previously unreported magnesium sulfate-associated gestational AVP disorder in the past 4 years alone, suggesting that many similar cases may be overlooked in clinical practice.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yanagisawa S, Oikawa Y, Endo M, et al. Magnesium sulfate may unmask subclinical excess vasopressinase-induced arginine vasopressin disorder. J Clin Endocrinol Metab. 2026. PMID: 41637052. doi:10.1210/clinem/dgaf695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。